The Lancet. Respiratory medicine
Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trial.
David J Jackson, Njira L Lugogo, Mark Gurnell, Liam G Heaney, Stephanie Korn, Guy Brusselle, Pascal Chanez, Ricardo Del Olmo, Jean-Pierre Llanos, Nanna Keeling, Kinga Sałapa, Bill Cook, Amit D Parulekar, Konstantinos Kostikas, Robert Fogel
Published: 202510.1016/S2213-2600(25)00359-5
Abstract
BACKGROUND: The SOURCE phase 3 oral corticosteroid (OCS)-sparing study of tezepelumab indicated an OCS-sparing effect with tezepelumab versus placebo in patients with OCS-dependent asthma and baseline blood eosinophil counts (BECs) of at least 150 ce…
Preview only. Read the full abstract at the source